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Summary The aim of this pharmacokinetic/pharmacodynamic study was to define the relationships of the
carboplatin exposure with the toxicity in patients treated with high dose carboplatin (400 mg m 2 day-'),
cyclophosphamide (1500 mg m-2 day-l) and thiotepa (120 mg m-2 day-l) for four consecutive days,
followed by peripheral stem cell transplantation. Exposure to carboplatin was studied in 200 treatment days
by measuring the area under the carboplatin plasma ultrafiltrate (pUF) concentration vs time curve (AUC).
The AUC was obtained by using a previously validated limited sampling model. A total of 31 patients was
studied who received one, two or three courses of this high-dose chemotherapy reigmen. The unbound, plasma
ultrafiltrate carboplatin was almost completely cleared from the body before each next treatment day in a
course; the day-to-day AUC variation was 3.3%. The mean cumulative AUC over 4 days was 19.6 (range
14.1-27.2) mg ml' min'. In 97 treatment days the carboplatin dose was calculated using the Calvert
formula with the creatinine clearance as the measure for the glomerular filtration rate (GFR). For these
courses, the inter-patient variability in pharmacokinetics was significantly reduced from 21% to 15% (P =
0.007) in comparison with the schemes where it was given as a fixed dose of 400 mg m 2. There were no
relationsips found between toxicity and the AUC of carboplatin, which may be due to the influence of
overlapping toxicities of cyclophosphamide and thiotepa. However, the ototoxicity was strongly related to the
cumulative carboplatin AUC. This toxicity was dose limiting for carboplatin in this schedule. It appeared that
the carboplatin pharmacokinetics in these regimens were similar to those reported at conventional dosages. To
reduce the inter-patient variation, the carboplatin dose can be calculated using the Calvert-formula with the
creatinine clearance as the measure for the GFR.
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Carboplatin (cis-diammine 1,1-cyclobutane dicarboxylate
platinum (II), CBDCA, JM8, NCS-241240, Paraplatin) is a
second-generation platinum-containing chemotherapeutic
compound, with established activity against a variety of
solid tumours (Wagstaff et al., 1989). Given at the
conventional dose of 350-400 mg m-2 every 4 weeks,
carboplatin is much less nephrotoxic, neurotoxic and
emetogenic than its parent compound cisplatin (Vermoken
et al., 1993). Its dose-limiting toxicity is myelosuppression,
predominantly thrombocytopenia. It has been reported that
the degree of myelosuppression is related to the exposure to
carboplatin, expressed by the area under the plasma
ultrafiltrate (pUF) concentration vs time curve (AUC)
(Calvert et al., 1989; Van der Vijgh 1991; Jodrell et al.,
1992; Reyno et al., 1993). The relationship between the
clearance of the drug and the glomerular filtration rate
(GFR) has led to the development of a formula by which the
dose can be calculated that results in a certain exposure
(target AUC) to carboplatin (Calvert et al., 1989). By using
this formula, approximately equal AUCs can be achieved in
each patient, yielding better predictive toxicity, and, possibly,
higher efficacy in patients with a high GFR.
In contrast to experiences with cisplatin, it has been
shown that with appropriate haematological support further
escalation of the carboplatin dose is possible to 800 mg m-2
and higher (Reed et al., 1993; Ozols et al., 1987; Motzer et
al., 1993; Newell et al., 1987; Shea et al., 1989, 1993;
Nichols et al., 1992). The use of higher doses of
chemotherapy may be beneficial, since it has been shown
to provide more long-term remissions in poor risk patients
with various malignancies (Ozols et al., 1987; Shea et al.,
1989; Nichols et al., 1992; Siegert et al., 1994; Antman et al.,
1990; Cheson et al., 1989). The relative lack of non-
haematological toxicities makes carboplatin an attractive
drug in the setting of high-dose chemotherapy, where
recovery from myelosuppression can be accomplished by
autologous bone marrow transplantation or peripheral blood
stem cell transplantation (PBSCT). However, when very high
doses carboplatin are administered, non-haematological
toxicities such as neurotoxicity, ototoxicity and nephrotoxi-
city become dose limiting (Ozols et al., 1987; Nichols et al.,
1992; Siegert et al., 1994; Elias et al., 1991). The degree of
these toxicities is difficult to predict and their extents vary
considerably among patients (Ozols et al., 1987; Motzer et
al., 1993; Newell et al., 1987; Nichols et al., 1992). A
plausible explanation might be the interindividual difference
in exposure to the drug (AUC), as has been established at
conventional doses for the myelosuppression. However, at
very high doses, information about the pharmacokinetics of
carboplatin and the relationships between the AUC and the
dose-limiting toxicities are scarce. Therefore, we initiated a
pharmacokinetic/pharmacodynamic study, with the following
aims:
(1) to determine the pharmacokinetic behaviour of carbo-
platin administered over four consecutive days;
(2) to test the day-to-day variation in drug exposure (AUC),
and to measure the possible occurrence of drug
accumulation;
(3) to determine the residual free carboplatin fraction before
the reinfusion of stem cells;
(4) to test the Calvert formula in this setting using the
creatinine clearance as a measure for the GFR;
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(5) to provide insight into the relationships between the
AUCs of carboplatin and clinical outcome.
The study has been conducted within a triple alkylator
protocol combining very high dose carboplatin
(1600 mg m-2) with thiotepa and cyclophosphamide (CTC)
followed by PBSCT, which is extensively used in the
Netherlands in the salvage treatment of germ cell cancer
and in breast cancer (Rodenhuis et al., 1992; Van der Wall et
al., 1994, 1995; Rodenhuis et al., 1995). For the pharmaco-
kinetic studies, we used a limited sampling procedure based
on only a single timed pUF drug determination for
estimating the AUC to reduce time, expenses and infection
hazards for the patient. This limited sampling procedure was
originally developed by S0rensen et al. (1993), and
prospectively validated for the CTC regimen (Van Warmer-
dam et al., 1994a).
Patients and methods
Patient selection
All patients were in partial or complete remission of
metastatic breast cancer with > 4 positive axillary lymph
nodes), refractory germ cell cancer, refractory ovarian cancer
or a refractory childhood tumour. Eligibility criteria included
a WHO performance status < 1, normal bone marrow
function (white blood cells (WBC) > 3.5 x 109 1-1 and
platelets > 100 x 1091 1), serum bilirubin < 25 ,uM, ALAT
and ASAT < 1.5 x the normal upper limit, creatinine
clearance > 50 ml min-', negative HIV test and all existing
infections had to be fully controlled. The protocol was
approved by the Institutional Ethical Committee and all
patients gave written informed consent. Additional eligibility
criteria for second or third transplantation procedures were
as follows: adequate stem cell harvest for three procedures
(i.e. > 3 x 106 kg-' CD34-positive cells per procedure),
absence of any infections, WBC > 2 x 109 1-l, absolute
neutrophil count (ANC) > 1.0 x 109 1-1, platelets > 20 x
109 1-1, creatinine clearance > 40 ml min-', ALAT and
ASAT < 2 x the upper normal limit, no severe symptomatic
neuropathy (> WHO grade II), and/or hearing loss (<
30 dB compared with healthy individuals), left ventricular
ejection fraction >0.50 and no life-threatening organ toxicity
from the first course. Patients with disease progression were
taken off study.
Treatment plan
Haematopoietic stem cells were mobilised with either 5-
fluorouracil (500 mg m-2), cyclophosphamide (500 mg m-2),
and epidoxorubicin (120 mg m-2) (in patients with breast
cancer) or with ifosfamide (4 g m-2) and etoposide
(300 mg m-2) (other solid tumours), both in combination
with granulocyte colony-stimulating factor (G-CSF, 300 ,g).
Peripheral stem cell harvesting, cryopreservation and reinfu-
sion were performed as previously described (Van der Wall et
al., 1994).
Carboplatin was administered as a 1 h infusion, followed
by cyclophosphamide (1500 mg m-2 day-') as a 1 h infusion
and thiotepa (2 x 60 mg m-2 day-') as 30 min infusions, all
on four consecutive days. For uroprotection, mercaptoetha-
nesulphonate (mesna, 500 mg) was co-administered intrave-
nously six times daily for six consecutive days, starting 1 h
before the first cyclophosphamide infusion. All infusions were
administered through a double-lumen Hickman catheter
inserted in a subclavian vein. Patients with single lumen
catheters were excluded from this study.
Chemotherapy was administered with a 5 week interval for
the double or triple transplantation programmes, with
PSBCT after each course. Peripheral stem cells were
reinfused 48 h after the last chemotherapy infusion.
The carboplatin dose was either based on the body surface
area (400 mg m-2 day-') for patients enrolled in the single
transplantation programme or was calculated employing the
Calvert formula substituting the creatinine clearance for the
GFR, for patients in the multiple transplantation pro-
gramme. The latter patients were dosed to achieve a total
target AUC of 20 mg ml-' min-' over 4 days by: dose
(mg day-') = 5 x [(creatinine clearance) + 25]. The
creatinine clearance was calculated by averaging the value
of a carefully collected 24 h urine collection and the value
obtained from the formula of Cockgroft and Gault (1976).
These values were obtained 1 or 2 days before starting each
course. The performance of the Calvert formula was
evaluated by the percentage MPE (MPE%), a measure of
bias, and the percentage RMSE (RMSE%), a measure of
precision (Van Warmerdam et al., 1994b):
N
MPE% = [N-' x Z(pei)] x 100%
i=l
N
RMSE% = [N-1 x Z(pei)']' x 100%
i=l
where N is the number of AUC pairs (i.e. targeted with
true values), and pe is the relative prediction error
[ln(AUCtargeted)-ln(AUCt,e value)]-
Supportive care
Details about the supportive care have been described
elsewhere (Rodenhuis et al., 1992; Van der Wall et al.,
1995). In summary, all patients received antiemetics
(including dexamethasone, ondansetron and temazepam),
and all patients received prophylactic antibiotics (including
ciprofloxacin, amphotericin B and penicillin G). Treatment
with aminoglycosides was avoided. Irradiated packed red
blood cells (RBCs) were routinely administered if the
haemoglobin (Hb) fell below 5.5 mmol 1-', and irradiated
platelet transfusions were given if the platelet count was
lower than 10 x 109 1-1 or in the case of haemorrhagic
diathesis. Patients were not discharged until WBC > 0.5 x
109 l-', without fever.
Pharmacokinetic studies
Complete concentration-time curves were obtained from
nine patients, who were sampled on day 1 (n =2), 2 (n = 3), 3
(n=2), or 4 (n=2) of their first CTC course. Samples were
collected at 12 time points: immediately before, halfway
through the infusion, at the end of infusion, and at 0.25, 0.5,
1.5, 2.75, 5, 8, 12, 18 and 24 h after the end of the infusion.
The blood samples of the other patients were collected at
only two time points: just before each carboplatin infusion
(blank), and at exactly 2.75 h after the end of the 60 min
infusion. An error in sampling time of maximally 5 min was
allowed. Samples were also taken at 24 and 48 h after the
fourth administration day to determine residual carboplatin
concentrations. All samples were collected in heparinised
tubes (5 ml) and taken through the double-lumen Hickman
catheter, using the lumen that was not used for the
administration of carboplatin. To avoid contamination of
the sample with any remaining fluid in this lumen, 10 ml of
blood was withdrawn and discarded before the actual sample
was taken.
Plasma was obtained by immediate centrifugation (5 min,
1500 g) of the samples. The plasma was transferred directly
to an MPS-1 system with a YMT-30 membrane (Amicon
Division, WR Grace, Danvers, MA, USA) and centrifuged
for 10 min at 1500 g. The obtained ultrafiltrate was stored at
-20°C until analysis. Urine was collected over 7 days:
starting before the first infusion and continuing up to 3 days
after the last infusion (the start of the PSBCT). Carboplatin
was quantitated using a validated method based on Zeeman
atomic absorption spectrometry (Van Warmerdam et al.,
1995).Clinical pharmacokinetics of high-dose carboplatin
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The complete pharmacokinetic curves (n =9) could be
described by a standard open two compartment model. The
AUC was calculated from these concentration -time curves
by the trapezoidal method with extrapolation to infinity
(Clast/)2; Clast is the last measured concentration and A2 the
elimination rate constant). Pharmacokinetic parameters were
calculated using standard equations (without weighting)
(Gibaldi and Perrier, 1982), using the pharmacokinetic
software package MW/Pharm (MEDI\WARE, Groningen,
The Netherlands). This programme was also used to fit
multiple dosing data using one complete pharmacokinetic
curve and only two time points for the other administration
days (Figure 1). For the other patients, the AUCs were
calculated using a limited sampling model (S0rensen et al.,
1993; Van Warmerdam et al., 1994a), where:
AUC (mg ml-' min-) =
0.52 (min) x (concentration at 2.75 h (mg ml-1) + 0.92 (mg ml-' min-')
Pharmacodynamic evaluations
The time of the haematological reconstitution was measured
by the number of days after the PBCST when the WBC
count had recovered to 0.2, 0.5 and 1.0 x 109 I`, the ANC
to 0.1, 0.5 and 1.0 x 109 1l,and the platelet count to 20, 50
and 100 x 109 1-1. Multivariate linear regression analysis,
analysis of variance (ANOVA) and the F-test were performed
using computer programme NCSS (version 5.0; J L Hintze,
East Kaysville, UT, USA). The evaluation of ototoxicity was
based on audiometric investigations by which the conven-
tional frequencies (250-8000 Hz) and the ultrahigh frequen-
cies (9000-18 000 Hz) were included. Audiograms were
obtained only from patients entered in the multiple
transplantation programme, just before the start of each
CTC course and about 1 month after the last. The loss in dB
was measured relative to the prePBSCT audiogram.
Results
Between July 1993 and July 1994 a total of 31 patients
underwent PBSCT for breast cancer (n= 21), testicular cancer
(n = 7), ovarian cancer (n = 2), and a rhabdomyosarcoma
(n= 1). These patients were part of several phase II clinical
trials, of which the detailed clinical results have been or will
be published elsewhere (Rodenhuis et al., 1992, Van der Wall
et al., 1995, Rodenhuis et al., 1995). Nineteen patients
received one CTC course, five patients two CTC courses and
seven patients three CTC courses. Thus, pharmacokinetic and
0 10 20 30 40 50 60 70 80 90 100
Time (h)
Figure 1 Typical plasma ultrafiltrate concentration time curves
for carboplatin. The curves for days 2, 3, and 4 were simulated
using two timed samples.
pharmacodynamic data obtained from a total of 50 CTC
courses were analysed. The median age was 37 (range 18-50)
years, with creatinine clearances ranging between 61 and
167mlmin-'.
Toxicity
As anticipated, profound granulocytopenia, anaemia and
thrombocytopenia developed in all patients. The total
number of RBCs and platelet units transfused after two or
three CTC courses was similar to that required after a single
CTC course. The feasibility and toxicity of multiple courses of
CTC will be reported in detail elsewhere. Overall, patients
required a median of 8 units (range 4-26) of packed RBCs
and 8 (range 2-35) platelet transfusions until acceptable
haematological recovery occurred. The median length of
hospitalisation for each course (calculated from the day of
reinfusion) was 15 days (range 11-26). Other common
reversible toxicities included nausea, vomiting, neutropenic
fever, diarrhoea, mucositis and alopecia. Mild and rapidly
reversible elevations of the serum transaminase levels were
common. Three patients, however, developed elevation of the
transaminases, hepatomegaly and ascites, consistent with a
clinical diagnosis of veno-occlusive disease (VOD), which was
lethal in two patients. Renal toxicity, defined as increases in
serum creatinine levels to more than 1.5 times the baseline
value, was seen in 4 of 31 patients. This phenomenon occurred
several days after the administration of the CTC course. The
values declined to baseline levels within several weeks. For one
patient, however, further treatment with CTC was discon-
tinued for this reason, one patient had already completed three
CTC courses, and for the other two patients only a single CTC
course had been planned. Four other patients had falls in
creatinine clearances of over 25% but less than 50%, which
recovered within a few weeks. Two patients developed a
'hand-foot' syndrome. Neurotoxicity symptoms developed in
10 patients (six being grade 1, four being grade 2) during
treatment, which stabilised or improved when CTC was
discontinued. Symptoms consisted of numbness, tingling or
paresthesias, usually in hands and feet. Motor symptoms were
absent. Most of these patients (7 out of 10) had been
pretreated with cisplatin-containing regimens. Symptomatic
tinnitus or hearing loss occurred in 11 patients. This group
included all patients (n = 8) pretreated with cisplatin-contain-
ing regimens. One of these patients already complained after
the first CTC course of symptomatic hearing loss in his right
ear. He had a unilateral loss of > 10 dB (at 4000 Hz)
increasing to 40 dB at higher frequencies. Most other patients
(n = 7) developed clinical signs of ototoxicity after the second
CTC course, all being bilaterally affected.
Pharmacokinetics
Complete concentration-time curves were obtained from
nine patients, who were sampled on day 1 (n = 2), 2 (n = 3), 3
(n = 2), or 4 (n = 2) of their first CTC course (Table I). Figure
1 depicts a typical pUF concentration-time curve for
carboplatin obtained on day 1 with simulated curves for
the following days; the shapes of curves at other days were
similar. The pharmacokinetics of carboplatin coud best be
described with a standard open two-compartment model. The
mean values and ranges of the pharmacokinetic parameters
were tj: 1.4 (range 0.8-1.8) h and tsp: 6.3 (range 4.3-7.3) h.
The mean CL was 78.2 (range 69-93) ml min-1 m-2, and the
mean Vd was 42.6 (range 27-50) 1 m-2 (Table I). The
pharmacokinetic data of these nine patients were used to
confirm the validity of the limited sampling model, as
developed by S0rensen et al. (1993), for the CTC regimen
(Van Warmerdam et al., 1994a).
It appeared that 191 of 200 of the treatment days (i.e.
96%) were evaluable for pharmacokinetic analysis by using
the limited sampling procedure. Nine treatment days were not
evaluable owing to inadequate sampling collection (n =3), or
deviation of more than 5 min from the planned infusion timeClinical pharmacokinetics of high-dose carboplatin
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Table I Pharmacokinetics of ultrafiltrated carboplatin administered in combination with cyclophosphamide and thiotepa
Patient Dose AUC Creatinine ti, tip Cl Vd
number (mg m-2) (mg ml- min-) Cl (ml min-) (h) (h) (ml mim-1 m-2) (I m-2)
1 (1) 400 4.08 95.3 0.8 5.7 76.7 37.8
2 (3) 400 4.31 116.4 1.5 6.1 93.0 49.4
3 (2) 400 4.71 72.4 2.0 5.6 68.7 33.4
4 (3) 400 4.73 84.0 1.0 6.9 82.8 49.4
5 (4) 400 4.81 61.1 0.9 7.3 78.9 49.8
6 (4) 400 4.95 77.0 1.5 6.9 68.9 41.4
7 (2) 400 5.05 90.6 1.6 4.3 73.3 27.4
8 (1) 400 5.18 116.0 1.8 7.5 73.8 47.8
9 (2) 400 5.26 85.0 1.8 6.1 87.9 47.1
Mean 4.79 88.6 1.4 6.3 78.2 42.6
s.d. 0.39 18.6 0.4 1.0 8.35 8.15
AUC, area under the concentration-time curve; t-, and t1, initial and terminal half-lives; Cl, total body clearance; Vd, volume ofdistribution;
s.d., standard deviation. Patient number with the treatment day between brackets.
(n = 6). The overall AUC per day was 4.9 (s.d. 0.9; range
3.0- 8.2) mg ml - min-', resulting in a mean cumulative
AUC of 19.6 (s.d. 3.1; range 14.1-27.2) mg ml-1 min-' per 4
days (i.e. one CTC course). Most of the unbound carboplatin
had been cleared from the body after the end of the first,
second, third and fourth day of administration. The 'blank'
values, obtained 24 h after each carboplatin infusion, were
always below 0.7 mg `1 (mean: 0.17 mg 1-1), which is less
than 1.5% of the maximum concentration achieved.
Furthermore, the AUC values achieved on the first day of
administration were similar to and thus predictive for those
achieved on the following days, with a day-to-day variation
of only 3.3%. Thus, no cumulation of the free drug occurred
during the consecutive days of administration. Platinum was
no longer detectable in the pUF at the time of the PBSCT
reinfusion, which was 48 h after the last carboplatin infusion.
Measurement of the cumulative 24 h urine excretion of
carboplatin indicated that 59.1% (range 25-99%) of the
infused carboplatin dose was recovered in the urine as
platinum after the first infusion. The cumulative urine
excretion (calculated as the percentage of the total
administered dose) for the following days was 53.7%,
54.5%, 54.9%, 57.2%, 57.6% and 58.1% respectively.
To test the Calvert formula using the creatinine clearance
as the measure for the GFR, patients enrolled in the multiple
transplantation programme were dosed to achieve a target
AUC of 5 mg ml-' min-m per treatment day by: dose
(mg day-1) = 5 x [(creatinine clearance) + 25]. The mean
measured AUC of this group (n=79 treatment days) was
4.90 (range 3.8-6.8) mg ml- min-' (MPE% = -3.1%),
whereas the mean AUC of patients dosed by
400 mg m-2 day-' (n = 191 treatment days) was 4.89
(range 3.0-8.2) mg ml -' min-' (Figure 2). Although the
mean AUC was similar in both groups, by using the Calvert
formula the pharmacokinetic variability (RMSE%) was
significantly reduced from 21% to 15% (F-test; P = 0.007).
Pharmacokinetic/pharmacodynamic relationships
All registered toxicities were tested for their associations with
the cumulative carboplatin AUCs per 4 days, by multivariate
regression analysis. Neither the carboplatin AUCs, nor other
patient-specific data were related to the grade nor to the time
needed to recover from toxicities such as nausea, vomiting,
diarrhoea, neutropenic fever, mucositis, elevations of serum
transaminase levels or the haematological toxicities. The
frequency and grade of the peripheral neuropathies were also
not related to the carboplatin AUC, but were generally
present in patients pretreated with cisplatin. The haematolo-
gical reconstitution was primarily dependent on the size of
the graft reinfused (in terms of the total number of
granulocyte-macrophage colony-forming units (CFU-GM),
and the number of CD34 positive cells), as previously
reported (Van der Wall et al., 1994) and was not affected
by the AUC of carboplatin. The cumulative AUC achieved
after one, two or three CTC courses, however, was predictive
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Figure 2 Frequency percentage of the achieved AUC per day.
The AUCs achieved after using a dose of 400 mg m-2 are
indicated by solid bars and the AUCs after using a dose based on
the Calvert formula (target AUC = 5 mg ml' min 1) are
indicated by blank bars.
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Figure 3 Average loss in dB at a cumulative AUC of 10-
30 mg ml -min- (l), 30-50 mg ml- min- (O) and 50-
70 mg ml - min-l (A) at the frequency range 125- 18 000 Hz.
The 2 x standard deviation (s.d.) interval is indicated by bars.
for the ototoxicity. In Figure 3 patients have been stratified in
three cumulative AUC groups (being 10-30 (n =9), 30-50
(n =9) and 50-70 (n =6) mg ml-l min-' respectively),
picturing the loss in dB plotted vs the frequency range.
Hearing loss was not significant if the cumulative AUC was
below 30 mg ml-1 min-'. Above that value hearing loss
became clinically evident, although there was only a weak
relation between the subjective hearing loss ofthe patient and
the results of the audiometric testing. Hearing loss was morecmnici of high-dose cw--PI
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pronounced in patients who had previously been treated with
cisplatin-containing chemotherapy. The speech range (400-
4000 Hz) became affected above a cumulative AUC of
30 mg ml-' min-', with higher frequencies being most
affected (Figure 3).
Disasson
The pharmacokinetics of carboplatin at conventional doses
have been reported by several investigators (Van der Vijgh
1991). In this study, however, carboplatin has been
administered by an unusual schedule (daily, for four
consecutive days), and combined with two other alkylating
agents. Interest was, therefore, focused on the pharmacoki-
netics ofthe drug in this schedule and the extent ofinter- and
intra-patient variability in carboplatin exposure. The risk of
infection inherent to the sampling of blood and the
inconvenience for the patient precluded the withdrawal of
multiple samples from a large number of patients. Therefore,
we preferred a limited sampling model using only a single
timed blood sample. This model was previously developed by
S0rensen et al. (1993), and prospectively validated by us for
our CTC studies (Van Warmerdam et al., 1994a). A total of
191 of 200 timed concentrations could be used to calculate
the carboplatin AUC values. This shows that the limited
sampling model could easily and rapidly provide insight into
the pharmacokinetic behaviour of the drug. From the AUC
values and from the complete pharmacokinetic curves
obtained from nine patients, it can be concluded that the
kinetics of high dose carboplatin was similar to those
reported for conventional doses. Importantly, the AUC
value found on the first day was virtually equal to the
AUCs found on the following days. Consequently, there was
no cumulation of free platinum in plasma over the several
days of administration. Apparently, the concurrent use of
diuretics, antibiotics and high doses ofcyclophosphamide and
thiotepa did not influence the pharmacokinetics of the drug
to a measurable extent. Furthermore, at the time of PBSCT
reinfusion, residual carboplatin concentrations were below
the limit of detection (LOD) being 0.08 mg 1-1 of the assay,
suggesting that no significant interference with haematologi-
cal reconstitution would occur. That is in accordance with the
results that show that the number of reinfused progenitor
cells was the only predictive factor for bone marrow
reconstitution, a phenomenon that has also been reported
by others (Shea et al., 1993). Unfortunately, because of the
short follow-up, no evaluations of efficacy can be made at
this stage.
The relationship between the carboplatin dose, the
hepatotoxicity and the renal toxicity, as reported by others
(Shea et al., 1989; Siegert et al., 1994), has not been observed
in our group of patients. This might be explained by the fact
that the carboplatin dose was 1600 mg m-2 per course
compared to the 2000-2400 mg m-2 per course used by
others in phase I clinical trials (Shea et al., 1989, Siegert et
al., 1994). The cumulative AUC values were also not
predictive for the occurrence of veno-occulsive disease.
Another important result is that the use of the Calvert
formula led to an accurate calculation ofthe carboplatin dose
to achieve a target AUC of 5 mg ml-' min-' (MPE% of
only -3.1%). The GFR was estimated here by the creatinine
clearance and not by the 5'CrEDTA method as indicated by
Calvert et al., 1989. Although the creatinine clearance is not
as accurate as the 5'CrEDTA method, the use of the Calvert
formula significantly reduced the interpatient variability as
compared to the patients treated with 400 mg m-2 day-'.
That might be especially important for future high-dose
studies with a less homogeneous population, where a greater
variation in AUC values can be expected when patients
receive a dose based on the body surface area.
The lack of correlation of the carboplatin AUC with the
duration or grade of the non-haematological toxicities may
be explained by the partial overlapping toxicities of
cyclophosphamide and thiotepa. Knowledge of the AUC
values or other pharmacokinetic parameters of these drugs
could provide more insight into the pharmacokinetic/dynamic
relationships, but validated limited sampling models that
would facilitate large pharmacokinetic studies in this regimen
do not (yet) exist. The only toxicity related to the carboplatin
(cumulative) AUC was the ototoxicity, where the presence of
pretreatment with cisplatin was an important co-factor. It
must be noted, however, that the cumulative AUC is strongly
correlated with the cumulative dose (mg) of carboplatin
(r=0.92). Consequently, monitoring of the cumulative
carboplatin AUC to prevent or predict ototoxicity seems
not clinically useful. Ototoxicity remains problematic for the
patient at these high dosages and was the principal dose-
limiting toxicity of carboplatin. Presently, the only way to
prevent the carboplatin ototoxicity seems to be a limitation of
the cumulative AUC (or dose). Obviously, this could reduce
the efficacy of the regimen. However, if carboplatin peak
concentrations in future studies appear to be more important
for ototoxicity than the AUC [as has been described for
cisplatin (Pollera et al., 1988)], alteration of the administra-
tion schedule might mitigate the ototoxicity without altering
the carboplatin AUC.
In conclusion, the pharmacokinetics of carboplatin at a
dosage of 400 mg m-2 day-' or target AUC of 5 mg ml-'
min-' per day for four consecutive days in combination with
cyclophosphamide and thiotepa, are similar to those observed
when carboplatin is administered as a single agent at a
conventional dose intensity. The day-to-day variation is
extremely low. To reduce the inter-patient variation, the
carboplatin dose can be calculated using the Calvert formula
with the creatinine clearance as the measure for the GFR.
For these reasons, further pharmacokinetic monitoring of
carboplatin in the CTC regimen is not necessary. However,
insight into the pharmacokinetic behaviour of thiotepa,
cyclophosphamide and metabolites is needed to establish
more clearly their pharmacodynamic involvement in this
combination.
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